NCT04614363View on ClinicalTrials.gov

68 Ga-PSMA for High Risk Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

February 26, 2022

Study Completion Date

April 25, 2023

Conditions
Prostate CancerHigh Risk
Interventions
DRUG

68Ga-PSMA

All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.

Trial Locations (1)

77030

Houston Methodist, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER

NCT04614363 - 68 Ga-PSMA for High Risk Prostate Cancer | Biotech Hunter | Biotech Hunter